Sarcomatoid variant of urothelial carcinoma in the renal pelvis with brain metastasis: a case report

Hamid Nasrollahi, Faisal Ahmed, Ali Eslahi, Mehrdad Golmoradi Pilehroud, Akbar Safaei, Mohammad Reza Askarpour, Abdol Azim Khorshidi, Soorena Khorshidi

Corresponding author: Ali Eslahi, Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. alieslahi@yahoo.com

Received: 19 Sep 2021 - Accepted: 04 Mar 2022 - Published: 22 Mar 2022

Keywords: Brain metastasis, chemotherapy, sarcomatoid variant, urothelial carcinoma, case report

Copyright: Hamid Nasrollahi et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Hamid Nasrollahi et al. Sarcomatoid variant of urothelial carcinoma in the renal pelvis with brain metastasis: a case report. Pan African Medical Journal. 2022;41(233). 10.11604/pamj.2022.41.233.31688

Available online at: https://www.panafrican-med-journal.com/content/article/41/233/full

Sarcomatoid variant of urothelial carcinoma in the renal pelvis with brain metastasis: a case report

Hamid Nasrollahi, Faisal Ahmed, Ali Eslahi, Mehrdad Golmoradi Pilehroud, Akbar Safaei, Mohammad Reza Askarpour, Abdol Azim Khorshidi, Soorena Khorshidi

1Department of Radiation Oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, 2Department of Urology, Urology Research Center, Al-Thawra General Hospital, Ibb University of Medical Science, Ibb, Yemen, 3Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, 4Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, 5Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

*Corresponding author
Ali Eslahi, Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract

Sarcomatoid urothelial carcinoma (UC) of the renal pelvis is rare. It is a high-grade malignant tumor that contains both epithelial and mesenchymal elements. Brain metastases from renal pelvis UC are infrequent and represented in few cases. We report a 68-year-old female with a right renal mass diagnosed as a UC with a sarcomatoid variant. The patient underwent a right radical nephroureterectomy and received chemotherapy. She developed brain metastasis in the left temporal area two months later. Therefore, metastasectomy and palliative brain radiotherapy were performed for her. Sadly, her general condition worsened, and she passed away after one month. Brain metastasis in patients with UC is rare and poorly understood. Therefore, we describe the clinico pathological characteristics, including the clinical follow-up of our case with a focus on the treatment and outcome.

Introduction

Sarcomatoid urothelial carcinomas (UC) are rare urothelial malignancies with aggressive clinical behaviors, accounting for 0.3% of all urinary tract UC cases [1]. The first case of renal pelvis UC was reported by Piscioli et al. in 1984 [2]. Radical surgical resection of the tumor and chemotherapy remains the optimal treatment for this tumor. Brain metastasis is extremely rare in UC patients and represents 0.4% to 0.6% of all urinary tract UC cases [3]. To our knowledge, just a few cases of sarcomatoid UC of the renal pelvis with brain metastasis have been reported [4]. Therefore, we describe the clinico pathological characteristics, including the clinical follow-up of our case with a focus on the treatment and outcome.

Patient and observation

Patient information: a 68-year-old woman presented with mild right-side flank pain and intermittent hematuria in the last month. Her pain was not colicky and did not interfere with her routine life. There were no other urologic problems, such as dysuria, frequency, or dribbling. Her medical history was not significant.

Clinical findings: the patient vital signs were stable (blood pressure: 120/70mmHg, respiratory rate: 14 respirations per minute, pulse rate: 61 beats per minute). She was pale and had mild right flank tenderness.

Diagnostic assessment: urine analysis showed microscopic hematuria, and other blood tests and urine culture were normal. According to her signs and symptoms, an ultrasound was requested that showed a 5x4cm hypoechoic mass in the right mid-pole and lower pole of the kidney. Chest and abdominal computed tomography (CT) scans were done, showing a 5x4cm enhanced irregular soft tissue mass in the mid-pole extended to the lower pole of the right kidney without evidence of metastases (Figure 1).

Therapeutic interventions: she underwent a right radical nephroureterectomy. The pathological report confirmed the diagnosis of high-grade UC with sarcomatoid differentiation. An immuno histochemistry (IHC) study was done, revealing a positive reaction for pan-cytokeratin and GATA 3 on both epithelial and sarcomatoid components and a negative reaction for CK5/6, P63, PAX8, and CD10 confirming the diagnosis of the sarcomatoid variant of UC (Figure 2).

Follow-up and outcome of the interventions: the patient was referred to the oncology clinic for adjuvant treatment. She received chemotherapy with gemcitabine (1000mg/m² day 1 and 8) and cisplatin (75mg/m² day 1); she developed neutropenic after the 2nd and 3rd cycles of chemotherapy and was unable to continue the chemotherapy. Thus, tumor bed radiotherapy was started for her. She received 44 grays (Gy) in 22 fractions to the tumor bed and regional lymph nodes. After two months, she developed severe headaches, and magnetic resonance imaging (MRI) showed brain metastasis (in the left temporal lobe, 9mm peripheral ring-enhancing lesion with...
crescent increased attenuation and adjacent edema) (Figure 3). Then a metastasectomy was performed, and the pathology report showed metastatic carcinoma of the UC. The patient received palliative brain radiotherapy with a dose of 30 grays (Gy) in ten fractions, but her general condition worsened, and she passed away after one month.

**Patient perspective:** the patient's son mentioned that “I would like to thank everyone from the nurses to the physicians that helped us take care of my mother, from the day she went to the hospital to the day that she left us”.

**Informed consent:** a written informed consent was obtained from the patient's family for participation in our study.

**Discussion**

Clinically, primary renal pelvis sarcomatoid UC is rare. The average age of presentation of this disease is over 50 years, with a male-to-female ratio of approximately 2/3. Symptoms of this tumor such as flank pain, gross hematuria, hydronephrosis, and abdominal mass are frequently like those of other renal tumors. However, the higher-grade and stage, metastases at presentation, poor prognosis as well as aggressive nature are the main characteristics of sarcomatoid UC [4]. Our patient was a 68-year-old woman who had right flank pain and hematuria when she came in. The sarcomatoid variant of UC is rare and aggressive, with approximately 100 reported cases, the vast majority of which occur in the urinary bladder. These tumors are also known as carcinosarcoma and spindle cell carcinoma [5]. According to Lopez-Beltran et al. microscopically sarcomatoid urothelial carcinoma has a urothelial, glandular, or small cell component with varying degrees of differentiation, and carcinoma in situ is found in 30% of these cases [6]. Similarly, in our case, epithelial and mesenchymal elements were found. There has been no agreement between published papers on UC treatment with sarcomatoid variants. However, the main suggested treatment with prolonged patient survival is radical surgery with systemic chemotherapy and radiation therapy [7]. A recent study found that upper urinary tract sarcomatoid carcinomas expressed the epidermal growth factor receptor (EGFR), implying that molecular targeted therapy may be a promising potential therapeutic route [8]. The regimen suggested for metastatic sarcomatoid UC is gemcitabine and doxorubicin with an objective response rate of 16% and a median progression-free survival of 3.5 months [9]. In our case, the radical nephroureterectomy was performed, followed by chemotherapy administration. However, the patient developed a neutropenic fever. For that, the patient was switched to tumor bed radiotherapy.

Brain metastasis is extremely rare in UC patients and represents 0.4% to 0.6% of all urinary tract UC cases. Furthermore, the frontal lobe, parietal lobe, temporal lobe, basal ganglia or thalamus, occipital lobe, brainstem, and cerebellum were the most common sites for brain metastases, respectively [3]. Headache is the most common symptom in patients with brain metastasis, affecting roughly half of all patients. Additionally, focal neurologic dysfunction may represent 20% to 40% of patients with the most common hemiparesis [10]. Brain MRI is the best radiologic modality for detecting brain metastases because brain CT may underestimate the number of metastatic brain lesions [11]. The favorable prognostic factors for brain metastasis are younger age, high preoperative Karnofsky performance scale score, maximal radio-surgical dose to tumor margin, less sarcomatoid components, graded prognostic assessment (GPA) score of less than 2, and the long interval between the diagnosis of renal cancer and the onset of brain metastasis [1,3]. Previously published articles estimate that brain metastasis has a lower prognosis than other metastasis sites, with an average survival rate of 4-5 months following diagnosis and treatment of brain lesions [12], just like our patient who passed away after one month. The best cure for brain metastasis is
still unknown. Surgical resection, whole-brain radiation therapy, and stereotactic radiosurgery are the most popular procedures [13]. Thanks to fractionated radiation therapy, the median period of life has increased from 3 to 6 months. The majority of radiation oncology centers administer 30 to 40 gray (Gy) doses in 10 to 20 fractions [3]. In our patients, radiotherapy following metastasectomy was an option. Nobuyuki et al. presented a sarcomatoid variant UC in a 66-year-old man with brain metastasis who passed away after 4.8 months of treatment [1]. On the other hand, Fang et al. reported a left kidney UC with brain metastasis in a 55-year-old woman. The patient developed left frontal lobe brain metastasis ten months after renal surgery. For that, metastasectomy was performed, and the patient had no sequelae within one year of follow-up [14].

Conclusion

Despite the rarity of UC metastasis to the brain, it is essential to consider the urinary tract system as the primary site of brain metastasis. Additionally, sarcomatoid UC with brain metastasis has a poor prognosis and low patient survival.

Competing interests

The authors declare no competing interest.

Authors' contributions

Patient management: Hamid Nasrollahi and Faisal Ahmed; data collection: Ali Eslahi, Mehrdad Golmoradi, and Akbar Safaei; manuscript drafting: Mohammad Reza Askarpour and Abdol Azim Khorshidi; manuscript revision: Soorena Khorshidi, Faisal Ahmed. All the authors have read and agreed to the final manuscript.

Acknowledgments

The authors would like to thank Shiraz University of Medical Sciences, Shiraz, Iran, Center for Development of Clinical Research of Nemazee Hospital, and Dr. Nasrin Shokrpour for editorial assistance.

Figures

Figure 1: abdominal computed tomography (CT) scan demonstrates a mass in the right renal pelvis (arrow)
Figure 2: sections of renal mass show infiltrative epithelial nests in renal parenchyma: A) with foci of sarcomatoid feature; B) immunohistochemistry shows a positive reaction for pan-cytokeratin; C) GATA3; D) X200
Figure 3: brain magnetic resonance imaging (MRI) shows brain metastasis (arrow)

References

1. Kikuno N, Kennoki T, Fukuda H, Matsumoto Y, Tsunoyama K, Ban S et al. Brain metastasis in a patient with a sarcomatoid variant RCC with well-controlled extracerebral metastases by temsirolimus. Anticancer Res. 2012 Aug;32(8): 3443-7. PubMed | Google Scholar
2. Piscioli F, Bondi A, Scappini P, Luciani L. 'True' sarcomatoid carcinoma of the renal pelvis. First case report with immunocytochemical study. Eur Urol. 1984;10(5): 350-5. PubMed | Google Scholar
3. Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg. 2003 Feb;98(2): 342-9. PubMed | Google Scholar
4. Acikalin MF, Kabukcuoglu S, Can C. Sarcomatoid carcinoma of the renal pelvis with giant cell tumor-like features: case report with immunohistochemical findings. Int J Urol. 2005 Feb;12(2): 199-203. PubMed | Google Scholar
5. Venyo AK, Titi S. Sarcomatoid variant of urothelial carcinoma (carcinosarcoma, spindle cell carcinoma): a review of the literature. ISRN Urol. 2014 Jan 22;2014: 794563. PubMed | Google Scholar

6. Lopez-Beltran A, Pacelli A, Rothenberg HJ, Wollan PC, Zincke H, Blute ML et al. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol. 1998 May;159(5): 1497-503. PubMed | Google Scholar

7. Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J. 2009 Dec;3(6 Suppl 4): S193-8. PubMed | Google Scholar

8. Wang X, MacLennan GT, Zhang S, Montironi R, Lopez-Beltran A, Tan PH et al. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. Hum Pathol. 2009 Feb;40(2): 211-7. PubMed | Google Scholar

9. Staehler M, Haseke N, Roosen A, Stadler T, Bader M, Siebels M et al. Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res. 2010;15(7): 287-91. PubMed | Google Scholar

10. Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology. 1993 Sep;43(9): 1678-83. PubMed | Google Scholar

11. Schaefer PW, Budzik RF, Jr, Gonzalez RG. Imaging of cerebral metastases. Neurosurg Clin N Am. 1996 Jul;7(3): 393-423. PubMed | Google Scholar

12. Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbavinar FF et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer. 2008 Oct 1;113(7): 1641-8. PubMed | Google Scholar

13. Fokas E, Henzel M, Hamm K, Surber G, Kleinert G, Engenhart-Cabillic R. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery: analysis of 88 patients. Strahlenther Onkol. 2010 Apr;186(4): 210-7. PubMed | Google Scholar

14. Fang WK, Jou YC, Dai YC, Ko PC, Huang YF. Brain metastasis from renal urothelial carcinoma successfully treated by metastasectomy. Ci Ji Yi Xue Za Zhi. Jan-Mar 2018;30(1): 41-43. PubMed | Google Scholar
Figure 1: abdominal computed tomography (CT) scan demonstrates a mass in the right renal pelvis (arrow)
Figure 2: sections of renal mass show infiltrative epithelial nests in renal parenchyma: A) with foci of sarcomatoid feature; B) immunohistochemistry shows a positive reaction for pan-cytokeratin; C) GATA3; D) X200
Figure 3: brain magnetic resonance imaging (MRI) shows brain metastasis (arrow)